moomoo ID:0
Log Out
  • English
  • 中文繁体
  • 中文简体

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Benzinga Real-time News ·  09/29 04:10  · Markets
  • One of the most-watched Alzheimer's therapies in the clinic, $Biogen(BIIB.US)$ Inc-Eisai Limited's (OTC:ESALY) experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months in early Alzheimer's.

  • In July 2022, the FDA accepted the marketing application for lecanemab under the accelerated approval pathway and granted a Priority Review. The PDUFA date is Jan. 6, 2023.

  • Several stocks related to Alzheimer's programs are gaining. SVB Leerink said these positive results would reinvigorate the Alzheimer's space.

$Eli Lilly and Co(LLY.US)$ - Market cap: $317 billion.

  • Positive readthrough is expected from its anti-amyloid beta donamemab in the first half of 2023.

  • In an exploratory analysis, the first analysis found that patients who received donanemab showed a more significant change in amyloid plaque levels, which was "highly associated with less cognitive decline."

$ROCHE HOLDING AG(RHHBY.US)$-Market cap: $267 billion.

  • Along with crenezumab, Roche is also evaluating gantenerumab in collaboration with $MorphoSys(MOR.US)$ in autosomal dominant Alzheimer's disease, as well as for preventing sporadic Alzheimer's and treating early Alzheimer's in late-stage trials.

  • Gantenerumab received FDA Breakthrough Designation.

$Novo-Nordisk A/S(NVO.US)$ - Market cap: $224 billion.

  • Oral semaglutide is currently in Phase 3 studies for early Alzheimer's disease that are expected to complete in 2025.

$Cassava Sciences(SAVA.US)$ - Market cap: $1.75 billion

  • Simufilam, Cassava's Alzheimer's candidate, is a small molecule (oral) drug that restores the normal shape and function of altered filamin A protein in the brain.

  • Mired by controversy on fabricated data for the candidate. Recently received Journal of Prevention of Alzheimer's Disease said no evidence to support data manipulation allegations.

$Prothena(PRTA.US)$ - Market Cap: $2.72 billion.

  • Initiated a Phase 1 study of PRX012, a next-generation anti-amyloid beta (Aβ) antibody for Alzheimer's disease. PRX012 received FDA Fast Track designation.

  • A Phase 1 study of PRX005, a humanized monoclonal antibody for Alzheimer's disease, in collaboration with $Bristol-Myers Squibb(BMY.US)$.

$AC Immune(ACIU.US)$ - Market Cap: $260 million.

  • Crenezumab is an investigational treatment discovered by AC Immune and designed to neutralize a pathological species of the beta-amyloid protein called oligomers.

  • In June, disappointing data from a Phase 2 study was announced in collaboration with Roche.

$Acumen Pharmaceuticals(ABOS.US)$ - Market cap: $388 million.

  • ACU193 is an antibody against amyloid-beta oligomers for early Alzheimer's disease for the company listed in 2021.

  • Topline results from INTERCEPT-AD Phase 1 trial are expected in 1H 2023.

  • Phase 2/3 clinical trial preparation activities are progressing.

$Alzamend Neuro(ALZN.US)$ - Market cap: $113 million.

  • Lead product AL001. Data showed that salicylate plasma concentrations were well-tolerated and consistently within safe limits. In May 2022, Phase 2 multiple-ascending dose study was initiated in Alzheimer's patients.

$Annovis Bio(ANVS.US)$ - Market Cap: $111 million.

  • Buntanetap is the lead compound. It is in clinical trials for Parkinson's and Alzheimer's.

  • Buntanetap-treated AD patients showed a statistically significant cognitive improvement of 30% compared with baseline results. Buntanetap is the only drug to improve cognition in AD patients and motor function in PD patients.

$Longeveron(LGVN.US)$ - Market Cap: $89 million.

  • In January, it initiated a Phase 2a trial evaluating Lomecel-B as a treatment for Alzheimer's disease (AD).

  • The study is at the 50% enrollment threshold (n=24 patients randomized) and remains on track to complete enrollment by the end of 2022.

$Cognition Therapeutics(CGTX.US)$ - Market cap: $39 million

  • Recently, it presented a proteomic analysis of clinical biomarker data from the SPARC study of CT1812 in mild-to-moderate Alzheimer's disease. The candidate demonstrated the effect of CT1812 on multiple Alzheimer's biomarkers.

  • Initiated dosing in Phase 2 SHINE study of CT1812 for mild-to-moderate Alzheimer's disease.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites and Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.